Skip to Content

Join the 'Ilaris' group to help and get support from people like you.

Ilaris News

New Drug, Canakinumab, May Fight Heart Disease in Whole New Way

Posted 28 Aug 2017 by Drugs.com

MONDAY, Aug. 28, 2017 – Move over, statins: New research finds that a medication aimed at dampening the body's inflammatory response may be a new tool to curb heart disease. The findings were presented Sunday at the European Society of Cardiology (ESC) Congress in Barcelona, Spain, and published in two major medical journals, The Lancet and the New England Journal of Medicine. The trial focused ...

FDA Approves Expanded Indications for Ilaris (canakinumab) for Three Rare Periodic Fever Syndromes

Posted 26 Sep 2016 by Drugs.com

September 23, 2016 – The U.S. Food and Drug Administration today approved three new indications for Ilaris (canakinumab). The new indications are for rare and serious auto-inflammatory diseases in adult and pediatric patients: Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS); Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD); and Familial Mediterranean ...

New Treatments Helping Kids With Juvenile Arthritis

Posted 20 Jul 2016 by Drugs.com

WEDNESDAY, July 20, 2016 – New treatments for juvenile arthritis offer hope to children with the chronic autoimmune condition, doctors say. Scientists are still working to understand what causes juvenile arthritis and how to stop its progression. But, kids coping with its effects have reason to be optimistic, according to Dr. Nikolay Nikolov, a rheumatologist and clinical team leader at the U.S. ...

Ilaris Approved by FDA to Treat Active Systemic Juvenile Idiopathic Arthritis

Posted 12 May 2013 by Drugs.com

Basel, May 10, 2013 - Novartis announced today that the US Food and Drug Administration (FDA) has approved Ilaris (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older. Ilaris is the first interleukin-1 beta (IL-1 beta) inhibitor approved for SJIA and the only treatment approved specifically for SJIA that is given as a ...

Drugs Hold Promise for Severe Juvenile Arthritis Patients

Posted 19 Dec 2012 by Drugs.com

WEDNESDAY, Dec. 19 – Children who suffer from a rare and painful form of arthritis that's accompanied by fever and rashes may soon have more treatment options. Two studies published in the Dec. 20 issue of the New England Journal of Medicine suggest that two drugs – canakinumab and tocilizumab – reduce symptoms, including severe joint pain experienced by children with systemic juvenile ...

Ask a Question

Further Information

Related Condition Support Groups

Familial Cold Autoinflammatory Syndrome, Familial Mediterranean Fever, Cryopyrin-Associated Periodic Syndromes, Juvenile Idiopathic Arthritis, Hyperimmunoglobulin D Syndrome, Muckle Wells Syndrome, Tumor Necrosis Factor Receptor Associated Periodic Syndrome

Ilaris Patient Information at Drugs.com